UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
Not Applicable | ||
(Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code: +
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered | ||
* | Not for trading, but only in connection with the listing of the American Depositary Shares on The Nasdaq Stock Market LLC. |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers |
On October 3, 2022, Viviane Monges notified the Board of Directors (the “Board”) of DBV Technologies S.A. (the “Company”) of her resignation from the Board and all committees thereof, effective immediately. Ms. Monges’s resignation was not the result of any dispute or disagreement with the Company or the Board.
In connection with Ms. Monges’s resignation, the Board appointed Timothy E. Morris, currently serving as independent director and member of the Audit Committee of the Board (the “Audit Committee”), as the Chairperson of the Audit Committee, in replacement of Ms. Monges.
In addition, Daniele Guyot-Caparros was appointed to the Board of the Company effective immediately, to fill the vacancy created by the resignation of Ms. Monges. Ms Guyot-Caparros’s appointment will be submitted to a shareholder vote at the next convened annual Ordinary and Extraordinary General Meeting of shareholders.
There are no arrangements or understandings between Ms. Guyot-Caparros and any other person pursuant to which Ms. Guyot-Caparros was appointed as a director. Ms. Guyot-Caparros does not have any family relationships with any of the Company’s directors or executive officers, and she does not have a direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.
Ms. Guyot-Caparros will be compensated in accordance with the Company’s non-employee director compensation policy. Ms. Guyot-Caparros will receive a fixed annual retainer of €100,000 per year for her service as a director.
In connection with her appointment to the Board, Ms. Guyot-Caparros plans to enter into the Company’s standard form of indemnification agreement, a copy of which was filed as Exhibit 10.3 to the Company’s Registration Statement on Form F-1/A (File No. 333-198870) filed with the Securities and Exchange Commission on October 15, 2014.
Item 7.01 | Regulation FD Disclosure. |
The Company issued a press release on October 3, 2022, announcing the director resignation and appointments described in Item 5.02. The press release making this announcement is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
The information in this Item 7.01, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits
Exhibit No. | Description | |
99.1 | Press Release dated October 3, 2022. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: October 4, 2022 | DBV TECHNOLOGIES S.A. | |||||
By: | /s/ Sébastien Robitaille | |||||
Name: | Sébastien Robitaille | |||||
Title: | Chief Financial Officer |
Exhibit 99.1
Montrouge, France, October 3, 2022 |
DBV Technologies Announces Appointment of New Chair of its Audit Committee and Appointment of Daniele Guyot-Caparros to Board of Directors
DBV Technologies (Euronext: DBV ISIN: FR0010417345 Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that Mr. Timothy E. Morris, Independent Director and Member of the Audit Committee of the Board of Directors (the Board), was appointed as Chairperson of the Boards Audit Committee in replacement of Ms. Viviane Monges, who resigned from the Board effective October 3, 2022. DBV also announced the Boards provisional appointment of Ms. Daniele Guyot-Caparros as Independent Director to fill Ms. Monges vacancy, effective October 3, 2022. With these changes, the Board comprises 10 members.
Mr. Morris has been a member of DBV Technologies Board and Audit Committee since April 2021. Mr. Morris has served as the Chief Operating Officer and Chief Financial Officer of Humanigen, Inc. since August 2020. He currently serves on the board of Aquestive Therapeutics (Nasdaq: AQST), Univercells S.A. and Humanetics (private). Mr. Morris has 38 years of professional finance and accounting experience, including 25 years as Chief Financial Officer of public biotechnology companies.
Ms. Monges served as a Member of the Companys Board and Audit Committee since May 2019 and Chairperson of the Boards Audit Committee since March 2021.
We are delighted to welcome Tim Morris to this new role as Chairperson of the Boards Audit Committee, said Michel de Rosen, Chairman of the Board. Tims financial acumen has been very useful to DBV Technologies since his joining the Board, and I am confident that his demonstrated expertise and experience will serve him well in this new capacity. On behalf of the Board, DBVs management team, and shareholders, I thank Viviane for her service and commitment to the Company. We greatly appreciate the leadership and insight Viviane has provided to our Board and its Audit Committee and wish her well in her next endeavors.
I have enjoyed my time as a Member of the Board of DBV Technologies and Chairperson of its Audit Committee. I believe in the Viaskin technology that DBV is working hard to develop and have confidence that it may one day bring significant benefit to patients if approved. I wish the best to the Company and to my colleagues of the Board, said Ms. Monges.
The Board of DBV Technologies has finalized the provisional appointment of a new Independent Director to fill the vacancy left by Ms. Monges and to join the Audit Committee of the Board. Ms. Daniele Guyot-Caparros joins as a new Independent Director to the Board, subject to ratification by the Companys shareholders at the next annual meeting of shareholders, and as a Member of the Boards Audit Committee. Ms. Guyot-Caparros has a longstanding track record in finance and business operations. She began her career in audit and corporate finance with PricewaterhouseCoopers (PwC) and later joined Rhône-Poulenc-Rorer (later Aventis and Sanofi) where she held several senior finance positions including Chief Financial Officer Global Research and Development and Chief Financial Officer Europe, Group Planning. Ms. Guyot-Caparros also held responsibilities in business development, pricing, and portfolio management. In 2008, Ms. Guyot-Caparros became Senior Advisor for Deloitte France to support the development of the Life Sciences and Health Care Industry practice.
I am thrilled to join DBV Technologies Board of Directors at a significant time in the Companys regulatory journey, said Ms. Guyot-Caparros. I am encouraged by the release of DBVs EPITOPE results in 1 to 3-year-old peanut allergic children and look forward to supporting the Companys continued progress with regards to the VITESSE Phase 3 pivotal study in 4 to 7-year-old peanut allergic children. These are critical age groups in this disease area, and families are long overdue for additional treatment options. I am eager to contribute to the responsible oversight of DBVs financial management to adequately support these and other clinical priorities.
In addition to in-house experience, Ms. Guyot-Caparros has held positions on the boards of biotechnology and medical technology companies. She was both a Board Member and Audit Committee Member at Diaxonhit (now Eurobio Scientific), listed on Euronext Growth. Ms. Guyot-Caparros was also Chairperson of the Audit Committee of Supersonic Imagine from July 2018 to September 2019 until its acquisition. From 2013 to 2022, she has been the Chairperson of the Audit Committee of Onxeo, and also served as the Chairperson of its Board of Directors from May 2019 to July 2021.
We welcome Daniele Guyot-Caparros as a new director to the DBV Board, said Michel de Rosen, Chairman of the Board. Daniele has rich experience in senior financial positions with diverse companies across the chemical, pharmaceutical and medical technology industries. She has served in prior board and audit committee positions where she has proven her strong leadership that will complement DBVs Board of Directors. Danieles appointment is part of our Board evolution as we continue to focus on having the right mix of skills and experience to achieve our strategic and financial objectives.
The provisional appointment of Ms. Guyot-Caparros will be submitted to a shareholder vote at the 2023 Ordinary and Extraordinary General Meeting. Details and procedures with respect to DBV Technologies 2023 Ordinary and Extraordinary General Meeting will be communicated by the Company at a later date.
About DBV Technologies
DBV Technologies is developing Viaskin, an investigational proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT, and is DBV Technologies method of delivering biologically active compounds to the immune system through intact skin. With this new class of non-invasive product candidates, the Company is dedicated to safely transforming the care of food allergic patients. DBV Technologies food allergies programs include ongoing clinical trials of Viaskin Peanut. DBV Technologies has global headquarters in Montrouge, France, and North American operations in Basking Ridge, NJ. The Companys ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and the Companys ADSs (each representing one-half of one ordinary share) are traded on the Nasdaq Global Select Market (Ticker: DBVT).
Forward-Looking Statements
This press release may contain forward-looking statements and estimates, including statements regarding DBV Technologies regulatory process, and the potential of DBV Technologies pipeline. These forward-looking statements and estimates are not promises or guarantees and involve substantial risks and uncertainties and may be impacted by market conditions as well as other risks and uncertainties set forth in DBV Technologies regulatory filings with the Autorité des Marchés Financiers (AMF), DBV Technologies filings and reports with the U.S. Securities and Exchange Commission (SEC), and future filings and reports made with the AMF and SEC. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements and estimates, which speak only as of the date hereof. Other than as required by applicable law, DBV Technologies undertakes no obligation to update or revise the information contained in this Press Release.
Investor Contact
Anne Pollak
DBV Technologies
+1 857-529-2363
anne.pollak@dbv-technologies.com
Media Contact
Angela Marcucci
DBV Technologies
+1 646-842-2393
angela.marcucci@dbv-technologies.com
Viaskin and EPIT are trademarks of DBV Technologies.
-?"BY\80^&[M?#MCIL]J;LEVNY&5@^Q> >F,5TU
M>6_O&,.:VAMW/@S5-(\.>,?$.N7D$VIZC9R!H[=3LC'7J>O0#\.IJ5--J**Y
M6DVR+X4^$M.?P9_PD$=HLVM%I3;RR$XC9
6QE
L(OE F&^(USN
M]\X+P[!K'1?(/QO_^S]G_1 *0F%?U=U06N$D8.J\T _#H%XJC4:CXK@CO:*0
MO1*\+N'K4J5<*5MEVZK8A:CFV./^MTRM4577L4].3DKZ;5QTKF32?J5&!?W@0[UV8"]<.'\<$;R1ZX@GJ@*=1W<"&7.GJ3
M)A;&BSU=*EUE]KZX2Q/(U3V:))#3XEU,"T'"@ 7)97N=RVW6N+SF%=^28_9C
MS>W*2OG #@.>@@_T1G2B"I'T]A-O"6Y:R/J[$_WO-!YG,,XXX-*S7V?T0Z +
MVWX4O+@"'&DX?% L5])8@ZP$&V2':&-9+L[ #T -5(9#J8^17W()*B^D0LO1
MA+%2<*VW>G>P5*>DY458)%WT%+=+"^Z'"*3QS7P]-/;,5Q2*3\B%E&@YL+3*
M*YY%)